Concepedia

HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib

Giorgio Valabrega, Sonia Capellero, Giuliana Cavalloni, Gianluca Zaccarello, Annalisa Petrelli, Giorgia Migliardi, Andrea Milani, Caterina Peraldo‐Neia, Loretta Gammaitoni, Anna Sapino,

Breast Cancer Research and Treatment · 2010 · 49 citations · 27 references

DOI

Concepts

References

27

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/<i>neu</i>Oncogene

Dennis J. Slamon, Gary M. Clark, Steven Wong et al. · Science · 1987 · 11.7K citations

, , +14

Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

Edward H. Romond, Edith A. Perez, John Bryant et al. · New England Journal of Medicine · 2005 · 5.4K citations · Full text

, , +17

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

Martine Piccart, Marion Procter, Brian Leyland‐Jones et al. · New England Journal of Medicine · 2005 · 5.1K citations · Full text

, , +16

Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

Charles E. Geyer, John Forster, Deborah Lindquist et al. · New England Journal of Medicine · 2006 · 3.5K citations · Full text

, , +17

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

Yoichi Nagata, Keng‐Hsueh Lan, Xiaoyan Zhou et al. · Cancer Cell · 2004 · 1.9K citations · Full text

, , +14